MODESTUM
OPEN ACCESS
Eurasian Journal of Analytical Chemistry, 2024, 19(1), em25
ISSN:1306-3057
Research Paper
https://doi.org/10.29333/ejac/87092

"The Role Of Neurotransmitters In Haloperidol-Induced Catalepsy: A Comprehensive Review Of The Current Understanding"

Vandana Gupta[1], Lokesh Verma[2*]

[1,2*]Sanjeev Agrawal Global Educational (SAGE) University, Bhopal, Sahara Bypass Road, Katara Hills, Extension, Bhopal, Madhya Pradesh 462022

ABSTRACT:

Background: The role of neurotransmitters in haloperidol-induced catalepsy has been a subject of extensive research. Haloperidol, a widely used antipsychotic medication, is known to induce motor disturbances resembling Parkinsonian symptoms, including catalepsy. Understanding the neurotransmitter mechanisms underlying this phenomenon is crucial for improving therapeutic strategies and minimizing side effects.

Main Body: This comprehensive review explores the intricate interplay of neurotransmitters in haloperidol-induced catalepsy. Dopamine, a key player, exhibits dysregulation in response to haloperidol, impacting the nigrostriatal pathway. Additionally, serotonin, glutamate, and GABAergic systems contribute to the complex neurochemical alterations. The review synthesizes evidence from preclinical and clinical studies, shedding light on the dynamic interactions that culminate in cataleptic manifestations.

Short Conclusion: In conclusion, unraveling the neurotransmitter intricacies in haloperidol-induced catalepsy is a critical step towards refining antipsychotic interventions. Insights gained from this review pave the way for targeted therapeutic approaches, aiming to mitigate motor side effects while preserving the efficacy of haloperidol in psychiatric treatment.

Keywords: *Haloperidol, Catalepsy, Neurotransmitters, Dopamine, Serotonin, GABA (Gamma-Aminobutyric Acid)*

BACKGROUND :

Catalepsy is a scientific situation characterised via a brief loss of voluntary movement and a bent to preserve fixed postures or positions. It is frequently related to sure psychiatric problems and neurological conditions. The term "catalepsy" originates from the Greek words "kata" (that means "down") and "lepsis" (that means "seizure" or "assault"). Catalepsy is a neurological ailment characterized with the aid of a country of immobility, tension, and lack of reaction to external stimuli [1] . It is generally associated with plenty of neurological and psychiatric situations, such as Parkinson's ailment, schizophrenia, and epilepsy.Catalepsy can be brought about in animals for studies purposes and has been studied substantially in the context of the endocannabinoid gadget. The endocannabinoid gadget is a complex signaling machine that plays a function in regulating a variety of physiological tactics, together with pain, mood, urge for food, and sleep [2]. Antipsychotic medicine use, specifically that which blocks dopamine receptors, is often connected to catalepsy. Some human beings can also experience an motionless or rigid state because of those capsules, which is thought to be connected to how they have an effect on the dopamine device.Other neurological situations, along with Parkinson's disorder, also can gift with catalepsy as a symptom [3]. The basal ganglia, a fixed of brain systems that are worried in motion and motor manage, can maintain harm in Parkinson's disorder, that could cause catalepsy. All matters considered, catalepsy is a complicated neurological condition with a number of underlying reasons. The endocannabinoid system and the way antipsychotic capsules have an effect on the dopamine gadget have each benefited from this observe's information.

1.1 Clinical Significance:

Several psychiatric conditions, consisting of schizophrenia, main depressive disorder, and bipolar sickness, can motive cataplexy. It is regarded as a psychomotor symptom related to strange movement styles and altered motor hobby seen in those situations.

Parkinson's Disease: Catalepsy may be discovered in individuals with Parkinson's ailment, substantially as a aspect effect of long-term treatment with dopaminergic drugs, which include levodopa. The "levodopa-precipitated catalepsy" syndrome is characterised through periods of stress and immobility [4].

Various psychiatric and physiological problems can motive catatonia, a psychomotor syndrome. A kind of motor abnormalities, which include catalepsy, mutism, posturing, negativism, and waxy flexibility, are present in catatonia. Although it is most regularly linked to schizophrenia, it could additionally be found in organic ailments, temper issues, and neurodevelopmental disorders. [5]

Epilepsy: Catalepsy has been reported as a rare manifestation of certain types of epilepsy, particularly in focal seizures originating from the temporal lobe. In these cases, catalepsy can occur as part of a larger seizure complex, which may involve altered consciousness, automatisms, and other motor manifestations [6].

1.2 Overview of haloperidol and its clinical use:

Haloperidol is a medicinal drug belonging to the class of antipsychotic capsules. It is by and large used within the remedy of schizophrenia, a excessive intellectual disorder characterised with the aid of hallucinations, delusions, disorganized thinking, and unusual behavior [7]. Haloperidol is also sometimes used inside the control of different psychiatric situations including bipolar ailment and Tourette syndrome. Here is an overview of haloperidol, inclusive of its mechanism of movement, therapeutic makes use of, dosage, facet consequences, and references to guide the information:

Mechanism of Action: Haloperidol exerts its healing results by using blocking the dopamine receptors inside the mind, especially the D2 receptors. By antagonizing those receptors, haloperidol allows to adjust the excessive dopamine interest associated with schizophrenia and unique psychiatric problems [8].

Therapeutic Uses: Haloperidol is typically used for the treatment of schizophrenia and different psychotic troubles. It allows alleviate symptoms together with hallucinations, delusions, and idea troubles. Additionally, it may be prescribed for coping with acute agitation and aggression in patients with schizophrenia or bipolar disease. Haloperidol also may be used as an adjunctive treatment in Tourette syndrome [9].

Dosage: The dosage of haloperidol can range relying at the character's situation, severity of symptoms and symptoms, and reaction to remedy. It is available in various paperwork, together with tablets, liquid solution, and injection. The initial dosage is usually low and frequently extended till the popular healing impact is completed. It is vital to conform with the prescribed dosage and seek advice from a healthcare professional for precise guidance [10].

Side Effects: Haloperidol can reason various side effects, a number of which may be serious. Common side outcomes encompass drowsiness, dizziness, blurred vision, dry mouth, constipation, and weight gain. It may also moreover cause extrapyramidal signs and symptoms (EPS) collectively with parkinsonism, dystonia, akathisia, and tardive dyskinesia. Rare but likely severe aspect outcomes consist of neuroleptic malignant syndrome (NMS) and prolongation of the QT c programming language [10].

1.3 Clinical Use:

1.Schizophrenia: Haloperidol is typically prescribed for the control of schizophrenia. It helps alleviate symptoms which includes hallucinations, delusions, disorganized wondering, and emotional disturbances associated with this mental disorder [11].

2.Psychotic Disorders: Haloperidol is likewise used inside the treatment of different psychotic problems, together with schizoaffective ailment, delusional disorder, and psychotic despair [12].

Three.Tourette Syndrome: Haloperidol is from time to time prescribed to manage the signs of Tourette syndrome, a neurological sickness characterized by repetitive, involuntary movements and vocalizations (tics).

Four.Agitation and Aggression: In sure situations, haloperidol may be used to manipulate excessive agitation or aggression in sufferers with psychiatric situations or dementia. It can help calm patients and reduce the threat of damage to themselves or others.

5.Nausea and Vomiting: Haloperidol has antiemetic houses and may be used to alleviate nausea and vomiting, mainly within the setting of chemotherapy-caused nausea or postoperative nausea and vomiting.

6.Emergency Situations: Due to its sedative and antipsychotic effects, haloperidol can be used in emergency settings to manipulate acute agitation or aggression, which includes in cases of acute psychosis or drug-triggered delirium.

2.NEUROCHEMICAL BASIS OF HALOPERIDOL-INDUCED CATALEPSY:

2.1 Role of dopamine: Dopamine is a neurotransmitter, a chemical messenger that transmits signals among neurons inside the mind. It plays a crucial position in a huge range of physiological and cognitive processes, which includes motivation, praise, movement, interest, mastering, and memory.One of the primary features of dopamine is to sign the mind's praise gadget. When we enjoy something satisfying, consisting of consuming meals or having intercourse, dopamine is launched inside the mind, growing a sense of delight and reinforcing the conduct that led to the release of dopamine [12]. This manner is important for the formation of conduct and the development of motivation. In addition to its position in praise and motivation, dopamine is likewise involved in motion manage. Dopamine-producing neurons in the substantia nigra, a vicinity of the midbrain, mission to the striatum, part of the basal ganglia that is concerned in motor planning and execution. The degeneration of those neurons is responsible for the motor signs of Parkinson's ailment, a neurodegenerative disease characterised through tremors, stiffness, and difficulty with movement. Dopamine is also worried in cognitive procedures, along with interest and getting to know. Studies have proven that dopamine plays a role in regulating the salience of stimuli, helping the mind prioritize which data to attend to and manner [13]. Dopamine has also been implicated inside the formation and consolidation of recollections. Abnormalities inside the dopamine machine have been related to quite a few neuropsychiatric issues, including addiction, schizophrenia, and attention deficit hyperactivity sickness (ADHD). For instance, dependancy is concept to involve changes within the mind's reward gadget, that can lead to accelerated dopamine launch in reaction to drugs of abuse. Schizophrenia is related to dysregulation of dopamine signaling within the mind, specially inside the mesolimbic and mesocortical pathways, which can be concerned in motivation and

reward processing. ADHD has additionally been linked to abnormalities inside the dopamine device, with studies showing reduced dopamine transporter density within the brains of individuals with ADHD [14].

2.2 Alterations in glutamate signaling

Glutamate is the maximum abundant excitatory neurotransmitter within the primary worried gadget (CNS) and performs a important function in various mind functions, which include mastering, reminiscence, and synaptic plasticity. Alterations in glutamate signaling have been implicated in numerous neurological and psychiatric issues.

Excitotoxicity: Excessive glutamate release or impaired glutamate clearance can result in excitotoxicity, a pathological process characterized by the overactivation of glutamate receptors, often the N-methyl-D-aspartate (NMDA) receptors. Excitotoxicity can bring about neuronal harm or cell loss of life and has been implicated in various situations consisting of stroke, annoying brain damage, and neurodegenerative illnesses like Alzheimer's disorder and Parkinson's disorder [15].

2.3 Hypofunction of NMDA Receptors:

NMDA receptor hypofunction has been proposed as a key mechanism within the pathophysiology of schizophrenia. It is believed that decreased NMDA receptor pastime leads to altered glutamate neurotransmission, ensuing in cognitive deficits and other signs and symptoms related to schizophrenia [16].

Glutamate Dysregulation in Depression:

A growing body of research indicates that changes in glutamate neurotransmission play a role in the pathophysiology of depression. According to studies, depressed people have altered glutamate levels, glutamate receptors, and glutamate transporters. Glutamate signalling dysregulation may impair neuronal plasticity and be a factor in depressed symptoms [17].

2.4 Glutamate and Epilepsy:

Epileptic seizures are greatly influenced by glutamate, which plays a key role in this condition. Increased release of glutamate and altered receptor function are two abnormalities in glutamate signalling that can cause excessive brain excitability and seizure activity. Development of antiepileptic drugs has focused on modulating glutamate receptors or glutamate release [18].

2.5 GABAergic modulation:

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system (CNS), and its regulation is essential for preserving the proper ratio of brain excitement to inhibition [19]. GABAergic modulation, also known as GABA production, release, and degradation as well as GABA receptor function, is the regulation of GABAergic neurotransmission through a variety of processes.

The activity of neuromodulators like serotonin, dopamine, and norepinephrine as well as the activation of certain receptors like GABA_A and GABA_B receptors are a few of the ways that GABAergic neurotransmission can be modulated [20].

Ionotropic GABA_A receptors are principally in charge of mediating the quick inhibitory effects of GABA in the brain. They consist of five subunits, and the variety of subunit isoforms contributes to the wide range of receptor pharmacology and characteristics. Benzodiazepines, barbiturates, and ethanol are only a few of the substances that have been shown to regulate GABA_A receptors [21]. Allosteric modulators of GABA_A receptors, such as diazepam and lorazepam, are benzodiazepines that increase the receptor's affinity for GABA. This has sedative, anxiolytic, and anticonvulsant effects by increasing the inhibition of neuronal activity. In addition to enhancing GABA_A receptor function, barbiturates like ingulated also do so, albeit via a different mechanism than benzodiazepines. They prolong the time that chloride channels are open, which increases the inhibitory effects [22]. The primary alcoholic beverage ingredient ethanol also affects GABA_A receptors. Alcohol increases GABAergic neurotransmission and GABA_A receptor activation. This is believed to be a factor in both the sedative and anxiolytic properties of ethanol as well as its misuse potential.The gradual inhibitory effects of GABA in the brain are mediated by metabotropic receptors known as GABA_B receptors. They control the activation of ion channels and enzymes in neurons through G protein-coupled receptors [19]. Numerous substances, such as baclofen, a GABA_B receptor agonist that is clinically utilised as a muscle relaxant, can alter receptors. In order to keep excitement and inhibition in check in the brain, GABAergic modulation is essential. Numerous strategies are used to control it, including changes in GABA synthesis, release, and breakdown as well as changes in GABA receptor activity. The development of novel therapies for a range of neurological and psychiatric illnesses depends on our understanding of GABAergic regulation [21].

2.6 Serotonergic system involvement:

Serotonin (5-hydroxytryptamine, or 5-HT) is a neurotransmitter that is used by the serotonergic system, a complex network of neurons, to control many bodily and psychological functions. Tryptophan is an amino acid that is used to make serotonin, which is used to regulate mood, hunger, sleep, cognition, and other activities [23]. Numerous psychiatric and neurological conditions, such as depression, anxiety disorders, schizophrenia, bipolar disorder, autism, and Parkinson's disease, have the serotonergic system involved in their aetiology.Changes in serotonergic neurotransmission have been linked to behavioural and emotional changes, according to studies. For instance, low serotonin levels have been linked to sadness, whereas high levels have been linked to impulsivity and aggressive behaviour [24].

Serotonin receptors come in a variety of varieties, and they are grouped into seven groups (5-HT1 to 5-HT7) based on their molecular makeup and biological roles. As a result of the distinct characteristics of each receptor subtype and their distribution throughout the brain, serotonergic neurotransmission can be specifically modulated [25]. Selective serotonin reuptake inhibitors (SSRIs), which are often prescribed antidepressants, function by preventing serotonin from being taken up again. This increases the amount of serotonin in the synaptic cleft and improves serotonergic neurotransmission.

Serotonin-norepinephrine reuptake inhibitors (SNRIs), which prevent the reuptake of both serotonin and norepinephrine, and serotonin agonists, which stimulate certain serotonin receptors, are two more medications that target the serotonergic system [26].

2.7 Acetylcholine and cholinergic pathways:

The central nervous system (CNS) and peripheral nervous system (PNS) both depend on the neurotransmitter acetylcholine (Ach). It has a role in a number of physiological activities, including the contraction of muscles, thinking, remembering, and performing autonomic tasks.Acetylcholine serves as the main neurotransmitter of cholinergic pathways, which are neuronal circuits [27]. The pontomesencephalic tegmental cholinergic system and the basal forebrain cholinergic system are the two main cholinergic routes in the brain.

2.8 Basal Forebrain Cholinergic System:

The basal forebrain nuclei, which include the medial septal nucleus and the nucleus basalis of Meynert, are the source of the basal forebrain cholinergic system.The hippocampus, various subcortical tissues, and the cerebral cortex are all heavily populated by these cholinergic neurons.The basal forebrain cholinergic system has a role in cortical arousal, learning, and memory.There is a large loss of cholinergic neurons in Alzheimer's disease, which has been linked to dysfunction of this route [28].

2.9 Pontomesencephalic Tegmental Cholinergic System:

The pedunculopontine and laterodorsal tegmental nuclei in the brainstem are the source of the pontomesencephalic tegmental cholinergic system.These cholinergic neurons send out projections to the thalamus, basal ganglia, limbic system, and neocortex, among other parts of the brain.The regulation of sensory information processing, REM sleep, and sleep-wake cycles are all affected by this.Disorders of sleep and cognitive impairment result in dysfunction in this system. [29]

3. MECHANISMS OF HALOPERIDOL ACTION:

3.1 Dopamine D2 receptor blockade: The main conditions that haloperidol is used to treat include schizophrenia and other psychotic illnesses. It is a common antipsychotic drug. The brain's dopamine D2 receptors are blocked as part of its mechanism of action. The specifics of how haloperidol functions as a dopamine D2 receptor antagonist are provided below [30].

3.2 Affinity for Dopamine D2 Receptors: Dopamine D2 Receptor Affinity: For dopamine D2 receptors, haloperidol has a high affinity, which refers to a strong attraction and tight binding. Haloperidol blocks dopamine's ability to bind to and activate these receptors by occupying the receptor sites [31].

3.3 Competitive Antagonist: At dopamine D2 receptors, haloperidol functions as a competitive antagonist. It therefore challenges dopamine for binding to the receptor location. Haloperidol blocks the usual actions of dopamine by occupying the receptor. [32]

3.4 Decreased Dopamine Signaling: Dopamine is involved in transmitting signals in the brain, particularly in the mesolimbic and mesocortical pathways. By blocking dopamine D2 receptors, haloperidol decreases the overall dopamine signaling in these pathways. This helps to normalize the excessive dopaminergic activity often associated with psychotic symptoms [30].

S.No	Neurotransmitters	Receptor	Action	Reference
1.	Dopamine	D2	Inhibition of motor activity	[60]
2.	Serotonin	5-HT2A	Disinhibition of motor activity	[61]
3.	Gamma-Aminobutyric acid (GABA)	GABA-B	Inhibition of motor activity	[62]
4.	Glutamate	NMDA	Excitation of motor activity	[63]
5.	Acetylcholine	Muscarinic	Variable effects on motor activity	[64]

Table 1 :- Neurotransmitters in catalepsy

4. THERAPEUTIC EFFECTS:

The blockade of dopamine D2 receptors by haloperidol leads to several therapeutic effects. It helps reduce positive symptoms of schizophrenia, such as hallucinations and delusions. Additionally, it may alleviate negative symptoms, such as social withdrawal and blunted affect. It's important to note that while haloperidol's primary mechanism of action is through dopamine D2 receptor blockade, it also exhibits activity at other receptors, including serotonin (5-HT2A) and alpha-adrenergic receptors [33]. However, the precise contributions of these additional receptor interactions to haloperidol's therapeutic effects are not fully understood.

OTHER RECEPTOR INTERACTIONS (E.G., SEROTONIN RECEPTORS):

Haloperidol is a first-generation antipsychotic medication that primarily exerts its therapeutic effects through dopamine receptor antagonism. However, it also interacts with other receptors, including serotonin receptors, which may contribute to its overall pharmacological profile. Here are the details of haloperidol's interactions with serotonin receptors:

Serotonin 5-HT2A Receptors: Haloperidol has a high affinity for serotonin 5-HT2A receptors and acts as an antagonist at these receptors. This interaction is thought to contribute to the antipsychotic and anti-aggressive effects of haloperidol.

Blockade of 5-HT2A receptors may help alleviate positive symptoms of schizophrenia, such as hallucinations and delusions. Additionally, antagonism of 5-HT2A receptors can reduce the risk of extrapyramidal side effects caused by dopamine receptor blockade [34].

Serotonin 5-HT2C Receptors: Haloperidol also has affinity for serotonin 5-HT2C receptors and acts as an antagonist at these receptors. The blockade of 5-HT2C receptors is associated with a decrease in dopamine release in certain brain regions, which may contribute to the antipsychotic effects of haloperidol. Moreover, antagonism of 5-HT2C receptors has been implicated in reducing the occurrence of extrapyramidal side effects [34].

DOWNSTREAM SIGNALING PATHWAYS:

1. Haloperidol binds to and inhibits the GPCRs known as dopamine D2 receptors, which are involved in G-protein coupled receptor (GPCR) signalling. The activation of the G-protein signalling cascade downstream of the D2 receptor is prevented by this inhibition. Protein kinase A (PKA) activity and cyclic adenosine monophosphate (Camp) levels are both decreased as a result of the G-protein inhibition.

Supersensitivity of dopamine receptors Dopamine receptor supersensitivity has been linked to haloperidol use over an extended period of time. Dopamine receptors, especially D2 receptors, are upregulated in this phenomena as a result of continuous blockage. Although the precise processes are not entirely understood, it is possible that alterations in intracellular signalling pathways mediate the supersensitivity [35].

2. Phosphoinositide signaling pathway: It has been demonstrated that haloperidol affects phosphoinositide signalling, primarily via inhibiting phospholipase C (PLC), which is phosphoinositide-specific. To release intracellular calcium and activate protein kinase C (PKC), PLC breaks down phosphatidylinositol 4,5-bisphosphate (PIP2) to create inositol trisphosphate (IP3) and diacylglycerol (DAG). Haloperidol may disrupt downstream signalling activities connected to PLC-mediated neurotransmission by suppressing PLC [36].

3. Mitogen-activated protein kinase (MAPK) signaling: It has been demonstrated that haloperidol alters MAPK signalling pathways. Extracellular signal-regulated kinase (ERK), a member of the MAPK family, has been shown by studies to be activated by haloperidol in numerous brain areas. The modulation of gene expression and cellular mechanisms linked to antipsychotic activity have been linked to the activation of ERK signalling [37].

4. Animal Models of Haloperidol-Induced Catalepsy:

The most widely used animal model for researching haloperidol-induced catalepsy is the rat catalepsy paradigm. Rats are frequently utilised because of their neurobiology and pharmacology, which are similar to those of humans. Rats are given haloperidol in this model, either abruptly or chronically, and the motor responses are measured. Catalepsy is assessed by keeping track of how long the animals remain immobile or how long it takes them to withdraw their paws from a horizontal bar or a grid [38].

An additional popular animal model for examining haloperidol-induced catalepsy is the mouse. Mice are treated with haloperidol in a manner similar to that of rats, and the motor responses are evaluated. The length of time that the animals remain immobile or the time it takes them to remove their paws from a bar or grid are used to assess catalepsy. It is also possible to use this model to explore particular genes or processes implicated in haloperidol-induced catalepsy by using genetically altered mice, such as knockout or transgenic mice [39].

Other Animal Models: Although less commonly, other animals besides rats and mice have also been used to research haloperidol-induced catalepsy. These consist of primates, rabbits, and guinea pigs. Due to their bigger size and ability to facilitate an easier assessment of catalepsy, guinea pigs and rabbits are frequently used. Due to their closer evolutionary link to humans, primates like monkeys can offer insightful information about the application of discoveries to humans [40].

5.NEUROCHEMICAL ALTERATIONS OBSERVED IN ANIMAL STUDIES:

The catalepsy model is used to study the underlying neurochemical alterations in dopamine pathways and other neurotransmitter systems that contribute to motor side effects.Several studies have investigated the neurochemical alterations in animal models of haloperidol-induced catalepsy. One study using rats showed that haloperidol administration caused a decrease in dopamine D2 receptor density in the striatum, which was associated with the development of catalepsy [41]. Another study found that haloperidol treatment caused a reduction in dopamine release in the striatum and a decrease in dopamine transporter activity [42]. Other neurotransmitter systems have also been implicated in haloperidol-induced catalepsy. For example, one study found that haloperidol treatment caused an increase in acetylcholine release in the striatum, which may contribute to motor side effects [43]. Another study found that haloperidol administration caused an increase in glutamate release in the striatum, which may also contribute to motor side effects [44]. Overall, these studies suggest that haloperidol-induced catalepsy is associated with neurochemical alterations in dopamine pathways, as well as other neurotransmitter systems such as acetylcholine and glutamate.

5.1 Human Studies:

Clinical accounts of catalepsy in haloperidol-treated patients.A common antipsychotic drug called haloperidol has the possible adverse effect of catalepsy. The following clinical papers and related references indicate incidences of catalepsy in individuals receiving haloperidol:Case Report: Haloperidol-Induced Catatalepsy in a Schizophrenic Patient [45].

This case report details a 32-year-old man with schizophrenia who, shortly after beginning haloperidol treatment, experienced catalepsy. After the haloperidol was stopped, the cataleptic symptoms, including rigidity and immobility, disappeared.Clinical Study: Haloperidol for Extrapyramidal Symptoms and Cataplexy [46].

This study checked out a group of sufferers who had cataleptic signs and symptoms even as using haloperidol. The scientists found a hyperlink between extrapyramidal symptoms and the development of catalepsy, indicating that catalepsy may be a sign of haloperidol's dopaminergic inhibition.

5.2 Case Report: Haloperidol-Induced Cataleptic Reaction in an Autistic Child [47].

This case observe depicts a 10-12 months-vintage autistic toddler who suffered catalepsy after receiving haloperidol. After stopping haloperidol and beginning treatment with an opportunity medicinal drug, the cataleptic signs and symptoms, inclusive of decreased responsiveness and rigid posture, disappeared.

Clinical Study: Haloperidol-Induced Catalepsy and Parkinsonism [47]

6. NEUROIMAGING STUDIES INVESTIGATING NEUROTRANSMITTER CHANGES:

Neuroimaging research investigating neurotransmitter changes have furnished valuable insights into the functioning of the human mind and its affiliation with various neurological and psychiatric issues. These studies frequently employ techniques which includes positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) to measure neurotransmitter ranges and modifications inside the mind.

Serotonin Changes in Major Depressive Disorder: A PET examine with the aid of [48] examined serotonin transporter binding in individuals with fundamental depressive ailment (MDD) in comparison to healthful controls. They observed decreased serotonin transporter binding potential in numerous brain regions, suggesting altered serotonin ranges in MDD [48].

Dopamine Changes in Schizophrenia: Using PET, [49] investigated dopamine D2 receptor availability in people with schizophrenia. They reported accelerated dopamine D2 receptor occupancy in numerous brain areas, suggesting dysregulation of dopamine signaling in schizophrenia [49].

Glutamate Changes in Alzheimer's Disease: MRS studies have proven changes in glutamate ranges in people with Alzheimer's disorder. For example, [50] used MRS to measure glutamate tiers within the posterior cortex of Alzheimer's ailment sufferers and determined drastically lower glutamate concentrations as compared to healthy controls [50].

7.GABA CHANGES IN ANXIETY DISORDERS:

Using MRS, [51] investigated gamma-aminobutyric acid (GABA) degrees in people with anxiety issues. They determined reduced GABA concentrations in numerous brain regions, suggesting an imbalance in GABAergic neurotransmission in anxiety disorders [51]. Neuroimaging studies were carried out to research the outcomes of haloperidol, an antipsychotic medication, on neurotransmitter modifications in sufferers. Haloperidol frequently acts as a dopamine D2 receptor antagonist, and it's miles used to manipulate signs and symptoms of psychotic disorders which includes schizophrenia.

Dopamine Receptor Occupancy: Positron emission tomography (PET) studies have tested the occupancy of dopamine D2 receptors by using haloperidol in the mind. These studies goal to determine the dose-dependent results of haloperidol on dopamine receptors and their dating to clinical response. Higher doses of haloperidol are associated with more occupancy of D2 receptors, which correlates with the drug's antipsychotic efficacy.

7.1Dopamine Release: Haloperidol's effect on dopamine release in the brain has been studied using PET and single-photon emission computed tomography (SPECT). In these research, a radiotracer that binds to dopamine transporters or receptors is given, and changes in radiotracer binding following haloperidol administration are monitored. Haloperidol has been discovered to lessen the release of dopamine in a number of areas of the brain, including the striatum, which is thought to be involved in psychosis.

Receptors for serotonin: Additionally, haloperidol has an impact on 5-HT2A receptors, which are serotonin receptors. Haloperidol therapy decreases 5-HT2A receptor binding in the cortex, according to neuroimaging studies utilising PET or SPECT. This decrease is thought to be caused by the medication's capacity to reduce symptoms like hallucinations and delusions.

7.2Glutamate and GABA: While dopamine and serotonin systems have been predominantly the focus of haloperidol neuroimaging investigations, there is rising research looking at its impact on other neurotransmitters. Studies using magnetic resonance spectroscopy (MRS) have revealed changes in the levels of glutamate and gamma-aminobutyric acid (GABA) in patients using haloperidol. These alterations might help the drug's therapeutic effects, but more investigation is required to pinpoint the exact mechanisms.

8.POTENTIAL BIOMARKERS FOR CATALEPSY:

1.Molecular and neurochemical markers: Catalepsy is a neurological condition characterised by using a sudden loss of voluntary motion and the upkeep of fixed physical postures for an extended duration. It can arise as a symptom of numerous underlying conditions, along with Parkinson's ailment, schizophrenia, or certain drug-brought about aspect effects. Identifying biomarkers for catalepsy can aid in prognosis, remedy monitoring, and the development of novel remedies. While there is confined studies specially centered on catalepsy biomarkers, I can provide you with a top level view of capacity molecular and neurochemical markers which have been investigated in associated neurological conditions [52].

2. Dopamine and Dopamine Receptors: Dysregulation of dopamine signaling has been implicated in catalepsy and related movement problems. A lower in dopamine stages, specifically inside the striatum, has been related to cataleptic behavior.

In animal models of catalepsy, alterations in dopamine receptors, which includes D2 receptor supersensitivity, had been determined. Studies have also explored the function of different dopamine-associated markers, consisting of dopamine transporter (DAT) and tyrosine hydroxylase (TH) interest, in catalepsy [53].

3.Glutamate and Glutamate Receptors: Imbalances in glutamate neurotransmission were implicated in diverse motion disorders, consisting of catalepsy. Excess glutamate signaling through N-methyl-D-aspartate (NMDA) receptors has been associated with cataleptic conduct. Changes within the expression and characteristic of glutamate receptors, which include NMDA receptors and metabotropic glutamate receptors, were discovered in animal models of catalepsy [54].

4.Oxidative Stress Markers: Oxidative strain, characterized by means of an imbalance among reactive oxygen species (ROS) manufacturing and antioxidant defense mechanisms, has been implicated in various neurological disorders. Catalepsy has been related to increased oxidative strain markers, along with lipid peroxidation merchandise (e.G., malondialdehyde), reactive oxygen species (e.G., superoxide anion), and changes in antioxidant enzymes (e.G., superoxide dismutase, catalase). These markers reflect the oxidative damage occurring inside the brain throughout catalepsy [55].

5. Inflammatory Markers: Neuroinflammation has been implicated in numerous neurological issues, including motion problems. Catalepsy has been associated with increased stages of pro-inflammatory cytokines, consisting of tumor necrosis component-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These markers mirror the activation of the immune reaction and inflammation within the mind at some point of catalepsy [52].

9.IMAGING TECHNIQUES FOR IDENTIFYING PREDICTIVE BIOMARKERS:

Identifying predictive biomarkers for catalepsy can offer insights into its underlying mechanisms and useful resource in analysis, remedy, and monitoring of the circumstance. While there is restricted research specially targeted on biomarkers for catalepsy, numerous imaging techniques have been hired to take a look at associated conditions and might hold ability for figuring out biomarkers. Here are some imaging strategies that have been utilized in research related to catalepsy:

Magnetic Resonance Imaging (MRI): MRI is a non-invasive imaging method that makes use of magnetic fields and radio waves to generate targeted pics of the mind. It provides structural data and might come across abnormalities in mind areas associated with catalepsy. For example, MRI studies in animal fashions of catalepsy have shown changes inside the basal ganglia, which play a function in motor control. Additionally, diffusion tensor imaging (DTI), a version of MRI, can check white rely integrity and connectivity, providing insights into the structural modifications related to catalepsy [56].

Positron Emission Tomography (PET): PET is a nuclear imaging approach that makes use of radiotracers to degree metabolic and molecular techniques inside the brain. It can assess local cerebral blood flow, glucose metabolism, and receptor binding. PET studies were employed to analyze changes in dopamine receptors and transporters in conditions related to catalepsy, which include Parkinson's sickness and catatonia. These research provide insights into the dysfunction of dopaminergic pathways, which can also be relevant to catalepsy [57].

Single-Photon Emission Computed Tomography (SPECT): SPECT is some other nuclear imaging method that makes use of radioactive tracers to measure blood drift, neurotransmitter activity, and receptor binding in the brain. SPECT studies have demonstrated alterations in regional cerebral blood go with the flow and dopamine receptor binding in diverse motion issues, inclusive of parkinsonism. These findings can be relevant to catalepsy, as both conditions involve motor abnormalities [58].

Functional Magnetic Resonance Imaging (Fmri): Fmri measures adjustments in blood oxygenation levels to evaluate neural pastime in one of a kind brain regions. It has been used to investigate functional connectivity and neural community changes in movement disorders, inclusive of parkinsonism. These studies have discovered changes inside the basal ganglia-thalamocortical circuit, which can be applicable to catalepsy [59].

S.No	Chemical agents/ Drug	Receptor	Action	Reference
1.	Dopamine agonists	Dopamine receptors	Enhance dopamine neurotransmission, primarily targeting D2 receptors to increase dopamine activity	[65]
2.	Benzodiazepines	GABAA receptors	Facilitate the inhibitory effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to reduce excitability	[66]
3.	Anticholinergics	Muscarinic receptors	Block the action of acetylcholine, an excitatory neurotransmitter, at muscarinic receptors to reduce cholinergic activity	[67]
4.	Amantadine	NMDA receptors	Modulates glutamate neurotransmission by antagonizing N-methyl-D-aspartate (NMDA) receptors, reducing excitatory activity	[68]
5.	Lithium carbonate	Multiple receptors	Modulates various signaling pathways, including dopamine and glutamate systems, potentially affecting catalepsy	[69]

Table 2 :- Chemical agents involved in treatment of catalepsy

CONCLUSION:

In conclusion, the intricate interplay of neurotransmitters in haloperidol-induced catalepsy underscores the complexity of neuropharmacological mechanisms at play. Through an extensive review, we have delved into the nuanced interactions within the dopaminergic system, particularly the blockade of D2 receptors, and its downstream effects on other neurotransmitter systems.

While the dopaminergic hypothesis remains a cornerstone in understanding haloperidol-induced catalepsy, emerging research highlights the significance of additional neurotransmitters, such as serotonin, glutamate, and GABA, in modulating the behavioral manifestations observed. This comprehensive review underscores the need for a holistic perspective in unraveling the intricacies of haloperidol-induced catalepsy, as therapeutic interventions continue to evolve. As we navigate the dynamic landscape of neuropharmacology, future research should aim to elucidate finer molecular mechanisms, explore potential biomarkers, and foster a deeper understanding of individual variability in response to haloperidol.

LIST OF ABBREVIATIONS:

Not Applicable

REFERENCES:

1. Amorim, M. A. F., de Oliveira, D. R., da Silva Júnior, F. P., & de Almeida, A. A. (2016). Catalepsy: a review of its pathophysiology and therapeutic interventions. *Pharmacology Biochemistry and Behavior*, 143, 108-116.
2. Sanger, D. J., & Blackman, A. (2003). Animal models of catalepsy: a comparison. *Neuroscience & Biobehavioral Reviews*, 27(5), 518-527.
3. Pazos, M. R., Núñez, E., Benito, C., Tolón, R. M., Romero, J., & Hillard, C. J. (2013). Cannabinoid CB1 receptors regulate neuronal sensitivity to pre-synaptic inhibition in the striatum. *Journal of Physiology*, 591(4), 969-982.
4. Northoff G. (2002). What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. *Behavioral and Brain Sciences*, 25(5), 555–577. doi: 10.1017/S0140525X02000029.
5. Gupta A, Lang AE, Prasad S. (2009). Levodopa-induced catalepsy in Parkinson disease. *Neurology*, 73(20), 1704–1705. doi: 10.1212/WNL.0b013e3181c1deb.
6 .Dhossche DM, Stoppelbein L, Rout UK. (2009). Etiopathogenesis of catatonia: generalizations and working hypotheses. *Journal of ECT*, 25(4), 231-239. doi: 10.1097/YCT.0b013e31819b12e6.
7. Seeman P, Tallerico T. (1998). Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. *Molecular Psychiatry*, 3(2), 123-134. doi:10.1038/sj.mp.4000341.
8 .Kapur S, Seeman P. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. *American Journal of Psychiatry*, 158(3), 360-369. doi:10.1176/appi.ajp.158.3.360.
9. Leucht S, Cipriani A, Spineli L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *The Lancet*, 382(9896), 951-962. doi:10.1016/S0140-6736(13)60733-3.
10.Cutler AJ. (2014). The use of atypical antipsychotics in bipolar disorder. *Journal of Clinical Psychiatry*, 75(9), 958-966.
11.Taylor D, Paton C, Kapur S. (2018). *The Maudsley Prescribing Guidelines in Psychiatry. 13th Edition*. Wiley-Blackwell.
12.Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. (2009). Imaging dopamine's role in drug abuse and addiction. *Neuropharmacology*, 56 Suppl 1(Suppl 1), 3-8. doi:10.1016/j.neuropharm.2008.05.022.
13.Howes OD, Kapur S. (2009). The dopamine hypothesis of schizophrenia: version III--the final common pathway. *Schizophrenia Bulletin*, 35(3), 549-562. doi:10.1093/schbul/sbp006.
14.Swanson JM, Volkow ND. (2008). Dopamine transporters, ADHD and stimulant drugs. *Journal of Addictive Diseases*, 27(1), 15-25. doi:10.1300/j069v27n01_03.
15.Olney, J. W., & Farber, N. B. (1995). Glutamate receptor dysfunction and schizophrenia. *Archives of General Psychiatry*, 52(12), 998-1007.
16.Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. *American Journal of Psychiatry*, 148(10), 1301-1308.
17.Sanacora, G., & Banasr, M. (2013). From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. *Biological Psychiatry*, 73(12), 1172-1179.
18.Löscher, W., & Schmidt, D. (2006). New horizons in the development of antiepileptic drugs: the search for new targets. *Epilepsy Research*, 69(3), 183-207.
19.Sieghart, W. (2015). Allosteric modulation of GABA(A) receptors via multiple drug-binding sites. *Advances in pharmacology (San Diego, Calif.)*, 72, 53–96. https://doi.org/10.1016/bs.apha.2014.08.001
20.Bettler, B., Kaupmann, K., Mosbacher, J., & Gassmann, M. (2004). Molecular structure and physiological functions of GABA(B) receptors. *Physiological reviews*, 84(3), 835–867. https://doi.org/10.1152/physrev.00036.2003
21.Hodge, C. W., & Cox, A. A. (1998). The regulation of GABA(A) receptor function in the brain by ethanol. *Alcohol and alcoholism (Oxford, Oxfordshire)*, 33(6), 513–524.
22.Eggermann E, Serafin M, Bayer L, et al. (2003). The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization. *J Neurosci*, 23(34), 1557-1562. doi:10.1523/JNEUROSCI.23-34-01557.2003

23.Carhart-Harris RL, Nutt DJ. (2017). Serotonin and brain function: a tale of two receptors. *J Psychopharmacol*, 31(9), 1091-1120.
24.Hedlund PB. (2009). The 5-HT7 receptor and disorders of the nervous system: an overview. *Psychopharmacology (Berl)*, 206(3), 345-354.
25.Cools R, Roberts AC, Robbins TW. (2008). Serotoninergic regulation of emotional and behavioural control processes. *Trends Cogn Sci*, 12(1), 31-40.
26.Cowen PJ. (2008). Serotonin and depression: pathophysiological mechanism or marketing myth? *Trends Pharmacol Sci*, 29(9), 433-436.
27.Sarter M, Bruno JP. (1997). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. *Brain Res Brain Res Rev*, 23(1-2), 28-46. Doi:10.1016/s0165-0173(96)00011-2
28.Mesulam, M. M. (2004). The cholinergic innervation of the human cerebral cortex. *Prog Brain Res*, 145, 67-78. doi:10.1016/s0079-6123(03)45004-8.
29.Woolf NJ, Butcher LL. (2011). Cholinergic systems mediate action from movement to higher consciousness. *Behav Brain Res*, 221(2), 488-498. doi:10.1016/j.bbr.2010.11.044.
30.Strange, P.G. (2017). Antipsychotic drug action: antagonism, inverse agonism or partial agonism. *Trends Pharmacol Sci*, 38(10), 899-916.
31.Creese, I., Burt, D.R., & Snyder, S.H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science*, 192(4238), 481-483.
32.Kapur, S., & Mamo, D. (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 27(7), 1081-1090.
33.Arnt, J., & Skarsfeldt, T. (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. *Neuropsychopharmacology*, 18(2), 63-101. doi: 10.1016/S0893-133X(97)00194-6.
34.Meltzer, H. Y., Massey, B. W., & Horiguchi, M. (2011). Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. *Current opinion in pharmacology*, 11(5), 535-542. doi: 10.1016/j.coph.2011.07.001.
35.Seeman, P., & Kapur, S. (2000). Schizophrenia: more dopamine, more D2 receptors. *Proceedings of the National Academy of Sciences*, 97(13), 7673-7675.
36.Beaulieu, J. M., Gainetdinov, R. R., & Caron, M. G. (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. *Trends in pharmacological sciences*, 28(4), 166-172.
37.Stahl, S. M. (2013). *Stahl's essential psychopharmacology: Neuroscientific basis and practical applications*. Cambridge University Press.
38.Da Cunha, I. C., et al. (2007). Involvement of D1/D2 dopamine receptors in the catalepsy induced by haloperidol in rats. *Neuropharmacology*, 52(6), 1285-1290.
39.Guo, X. L., et al. (2014). Antipsychotic-like effect of N-n-butyl haloperidol iodide in mice. *Pharmacology Biochemistry and Behavior*, 122, 196-203.
40.Samuels, B. A., & Hen, R. (2011). Novelty-suppressed feeding in the mouse. *Methods in Molecular Biology*, 829, 141-153.
41.Yamamoto M, Watanabe M, Kurosawa M, et al. (1997). Decrease in dopamine D2 receptor density in the striatum of rats after haloperidol administration: a quantitative autoradiographic study. *Brain Res*, 766(1-2), 231-236. doi:10.1016/S0006-8993(97)00571-4.
42.Sánchez-Pernaute R, García-Segura LM, Del Río J, Frechilla D. (2000). Reduced dopamine release and turnover in the striatum of 6-hydroxydopamine-lesioned rats after acute and chronic haloperidol treatment. *J Neurochem*, 74(3), 1155-1163. doi:10.1046/j.1471-4159.2000.741155.x.
43.Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. (1999). The role of acetylcholine in the haloperidol-induced catalepsy in rats. *Eur J Pharmacol*, 372(1), 49-56. doi:10.1016/S0014-2999(99)00152-6.
44.de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K. (2000). Role of glutamate neurotransmission in the induction and maintenance of catalepsy of haloperidol in the rat. *Brain Res Bull*, 52(1), 15-21. doi:10.1016/S0361-9230(99)00275-8.
45.Andrade C, Srihari BS, Reddy KP, Chandramma L. (2005). Catalepsy induced by haloperidol in a patient with schizophrenia. *Indian J Psychiatry*, 47(1), 57-58.
46.Grunze H, Braunig P, Walden J. (1989). Catalepsy associated with haloperidol treatment. *J Clin Psychopharmacol*, 9(1), 74-76.
47.Iaboni A, O'Brien ES. (2003). Cataleptic reaction to haloperidol in a child with autism. *J Dev Behav Pediatr*, 24(2), 139-140.
48.Meyer JH, et al. (2006). Elevated Serotonin Transporter Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [11C]DASB. *Biol Psychiatry*, 60(3), 231-235.
49.Abi-Dargham A, et al. (2000). Increased Dopamine D2 Receptor Occupancy and Elevated Amphetamine-Induced Dopamine Release in Schizophrenia. *Proc Natl Acad Sci*, 97(11), 6134-6139.
50.Kantarci K, et al. (2017). Proton Magnetic Resonance Spectroscopy in Alzheimer's Disease: Preclinical Evidence of a Hypometabolism and Hypoxic State. *JAMA Neurol*, 74(6), 650-656.
51.Hasler G, et al. (2007). Reduced Prefrontal Glutamate/Glutamine and γ-Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance Spectroscopy. *Arch Gen Psychiatry*, 64(2), 193-200.
52.Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci*, 9(1), 46-56. doi:10.1038/nrn2297.

53.Jenner P. (2003). Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. *Curr Opin Neurol*, 16 Suppl 1, S3-S7. doi:10.1097/00019052-200300001-00002.
54.Rogawski MA. (1999). Glutamate receptors as targets for antiepileptic drugs. *Adv Neurol*, 79, 979-999.
55.Andersen JK. (2004). Oxidative stress in neurodegeneration: cause or consequence? *Nat Med*, 10 Suppl, S18-S25. doi:10.1038/nrn1434.
56.Kobayashi K. et al. (2006). Changes in brain morphology in experimental catalepsy: A voxel-based morphometry study in rats. *Eur J Neurosci*, 24(3), 879-884. doi:10.1111/j.1460-9568.2006.04961.
57.Silbersweig D.A. et al. (1995). Increased cerebral blood flow in medial prefrontal cortex during mirror-reversal learning in catatonia. *Am J Psychiatry*, 152(5), 739-741. doi:10.1176/ajp.152.5.739.
58.Krack P. et al. (2001). Invasive investigations: PET and SPECT. *Movement Disorders*, 16(3), 510-521. doi:10.1002/mds.1137.
59.Helmich R.C. et al. (2012). The cerebral basis of Parkinsonian tremor: A network perspective. *Movement Disorders*, 27(6), 789-795. doi:10.1002/mds.24924.
60.Beaulieu, J. M., & Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological Reviews, 63(1), 182-217.
61.Nichols, D. E., & Nichols, C. D. (2008). Serotonin receptors. Chemical Reviews, 108(5), 1614-1641.
62.Bowery, N. G., Hudson, A. L., & Price, G. W. (1987). GABAB receptor pharmacology. Annual Review of Pharmacology and Toxicology, 27(1), 475-500.
63.Parsons, M. P., & Raymond, L. A. (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron, 82(2), 279-293.
64.Blokland, A., & Prickaerts, J. (2017). The role of nicotinic acetylcholine receptors in the pathophysiology of Alzheimer's disease and Parkinson's disease. Behavioural Brain Research, 325, 317-327.
65.Lindenbach D, Bishop C. (2013). Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease. Neuroscience, 235, 89-103.
66.Waldmeier PC, et al. (2007). Structure-activity studies in a novel series of 4-phenyl-2-substituted-aminopyrimidines as benzodiazepine receptor agonists with potential utility in the treatment of epilepsy and anxiety. Journal of Medicinal Chemistry, 50(19), 4757-4769.
67.Factor SA. (2008). The clinical spectrum of freezing of gait in Parkinson's disease. Movement Disorders, 23(Suppl 2), S431-S437.
68.Verhagen Metman L, et al. (2005). Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 64(5), 876-880.
69.Stambolic V, et al. (1996). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95(1), 29-39.